Salivary B-type natriuretic peptide: a new method for heart failure diagnosis and follow-up
Salivary B-type natriuretic peptide: a new method for heart failure diagnosis and follow-up
复制标题
DOI：
10.5603/kp.a2016.0097
复制
发表时间：
2017-01-01
影响因子：
3.3
通讯作者：
Bozorgi, Ali
中科院分区：
文献类型：
--
作者：
Joharimoghadam, Adel;Tajdini, Masih;Bozorgi, Ali
背景：频繁住院和生活质量下降是心力衰竭（HF）的主要并发症。血浆 B 型钠尿肽 (BNP) 水平被认为是筛查左心室功能障碍的一种经济有效的方法。关于 BNP 引导治疗的研究显示，心力衰竭的死亡或住院时间减少。 目的：由于唾液在采样方面比血液具有更少的限制，本研究的目的是测试唾液 BNP 浓度是否可能成为慢性心力衰竭患者的新生物标志物。方法：这项试点研究涉及 35 名被诊断为失代偿性心力衰竭的入院患者和 35 名到心脏病科接受检查的心力衰竭患者。对照组由 25 名没有心脏病史的人组成。收集所有参与者的唾液和血浆样本。 结果：与门诊心力衰竭患者（9.37 vs. 6.62 pg/mL，p < 0.001）和对照组（9.37 vs. 4.69 pg/mL，p < 0.001）相比，入院心力衰竭患者的平均血浆 NT-proBNP 水平较高。此外，入院心力衰竭患者的平均唾液 BNP 水平较高（6.50 ng/L，p < 0.001）；门诊心力衰竭组（5.87 ng/L，p = 0.02）与对照组（5.64 ng/L）相比。结论：我们的研究表明，唾液中可检测到 BNP，且心力衰竭患者（尤其是有症状的患者）唾液中水平较高。这意味着唾液 BNP 可能有助于心力衰竭患者的诊断和随访，尤其是在紧急情况下。
Background: Frequent hospital admissions and reduced quality of life are the main complications of heart failure (HF). Plasma B-type natriuretic peptide (BNP) levels have been considered as a cost-effective method of screening for left ventricular dysfunction. Studies regarding BNP-guided therapy revealed reduction in death or hospital stay for HF.Aim: As saliva has fewer limitations than blood in regard to sampling, the aim of the present study was to test if salivary BNP concentration might be a new biomarker in patients with chronic HF.Methods: This pilot study involved 35 admitted patients with decompensated HF diagnosis and 35 HF patients who had come for a check-up at the Department of Cardiology. The control group consisted of 25 people with no history of cardiac events. Saliva and plasma samples of all the participants were collected.Results: Mean plasma NT-proBNP was found at higher levels in admitted HF patients compared to outpatient HF (9.37 vs. 6.62 pg/mL, p < 0.001) and control groups (9.37 vs. 4.69 pg/mL, p < 0.001). Also, mean salivary BNP levels were higher in admitted patients with HF (6.50 ng/L, p < 0.001); and outpatient HF group (5.87 ng/L, p = 0.02) compared to the control group (5.64 ng/L).Conclusions: Our study demonstrated that BNP could be detected in saliva and that the level is higher in HF patients, especially symptomatic ones. This means that salivary BNP may be useful in the diagnosis and follow-up for patients with HF, especially in emergency settings.